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Therapeutic approaches which aim to target Acute Myeloid Leukaemia through enhancement of patients’ immune responses
have demonstrated limited efficacy to date, despite encouraging preclinical data. Examination of AML patients treated with
azacitidine (AZA) and vorinostat (VOR) in a Phase II trial, demonstrated an increase in the expression of Cancer-Testis Antigens
(MAGE, RAGE, LAGE, SSX2 and TRAG3) on blasts and that these can be recognised by circulating antigen-specific T cells.
Although the T cells have the potential to be activated by these unmasked antigens, the low arginine microenvironment
created by AML blast Arginase II activity acts a metabolic brake leading to T cell exhaustion. T cells exhibit impaired
proliferation, reduced IFN-γ release and PD-1 up-regulation in response to antigen stimulation under low arginine conditions.
Inhibition of arginine metabolism enhanced the proliferation and cytotoxicity of anti-NY-ESO T cells against AZA/VOR treated
AML blasts, and can boost anti-CD33 Chimeric Antigen Receptor-T cell cytotoxicity. Therefore, measurement of plasma arginine
concentrations in combination with therapeutic targeting of arginase activity in AML blasts could be a key adjunct to
immunotherapy.
Introduction
T cell immunity plays a key role in the body’s defence through
the recognition of foreign antigens, expansion in T cells, and sig-
nalling through cytokines and cell surface molecules. However,
in cancer patients, despite large numbers of abnormal cells being
present, immune surveillance is subverted such that T cells fail
to recognise the malignant cells or are inhibited in their prolifer-
ation or function. A resurgence of cellular immunotherapy strat-
egies has shown the potential for T cells to eradicate leukaemia.
Indeed, even relatively crude immune approaches such as allo-
geneic stem cell transplant in patients with high risk or relapsed
AML demonstrate the clinical benefit of T cell activity, despite
the risk of Graft Versus Host Disease.
Only a few new drugs have been developed for AML that have
significantly altered patient outcomes—of these epigenetic modi-
fiers such as azacitidine and vorinostat appear amongst the most
promising.1,2 One proposed mechanism of action is the upregula-
tion of MHC-restricted previously undetectable cancer-testis anti-
gens (CTAG) allowing antigen-specific T cells to recognise and
kill AML blasts.3 However, attempts to trigger autologous T cell
responses have led to only limited clinical improvements, with
the mechanism of failure poorly understood. Furthermore, the
mechanisms of how patients’ immune surveillance fails to control
leukemic expansion, have not been well characterised.
Recently the interaction between cancer cell metabolism and
immunity has become a focus in understanding cancer-immune
evasion. The consumption of amino acids such as arginine have
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been shown to impact T cell responses in the laboratory setting,
yet the translational importance of this mechanism in patients
has not been explored.4 Here we identify how the failure to
address the arginine metabolic microenvironment impacts
immune-modulatory epigenetic therapy or CAR-T cytotoxicity
against leukaemic blasts.
Materials and Methods
Patient samples and study approvals
Blood samples were obtained from 80 AML patients ineligible
for intensive chemotherapy treated with either azacitidine or
azacitidine and vorinostat in a multi-centre, randomised phase
II trial (RAVVA; NCT01617226).5 Fresh Peripheral Blood
Mononuclear Cells were separated using a Lymphoprep (Alere,
Stockport, UK) gradient and stored in liquid nitrogen. Samples
from healthy donors were obtained from the University of Bir-
mingham. In accordance with the Declaration of Helsinki, all
samples were obtained after written, informed consent prior to
inclusion in the study. Regional Ethics Committee (REC Number
10/H0501/39) approval for the study was granted.
RT-Q-PCR analysis
RT-Q-PCR was used to detect Cancer-Testis Antigens and
Arginase II in purified patient-derived AML blasts and cell
lines. RNA was extracted using an RNeasy Mini kit (Qiagen,
Venlo, Netherlands). cDNA was prepared using SuperScriptTM
III Reverse Transcriptase (Invitrogen, Carlsbad, CA) after the
manufacturer’s instructions. RT-Q-PCR was done in duplicate
using FAST SYBR Green Master Mix (Applied Biosystems, Fos-
ter City, CA) and the Applied Biosystems 7500 Fast Real-Time
PCR system. Analysis of gene expression was calculated accord-
ing to 2-ΔT method plotted as arbitrary units of mRNA relative
to GAPDH.13
Primer sequences (Eurofins) list
Human:
MAGE 5’-AGTCCTCAGGGAGCCTCC-3’ Forward
5’-ACTCAGCTCCTCCCAGATTT-3’ Reverse
LAGE 5’-GCAGGATGGAAGGTGCCC-3’ Forward
5’-CTGGCCACTCGTGCTGGGA-3’ Reverse
TRAG3 5’-CCAAAGAGGTTCCCAAGACA-3’ Forward
5’-GCTGTCCCGAAAAGAGACTGG-3’ Reverse
SSX2 5’-GTGCTCAAATACCAGAGAAG
ATC-3’
Forward
5’-TTTTGGGTCCAGATCTCTC
GTG-3’
Reverse
RAGE1 5’-AGTTCAAACAGGATC
AGGAATACCTC-3’
Forward
5’-TGCTCAGTTATCTTCCGCCTTTC-3’ Reverse
Arginase II 5’-ATGTCCCTAAGGGGCAGCCTCTC
GCGT-3’
Forward
5’-CACAGCTGTAGCCATCTGACAC
AGCTC-3’
Reverse
GAPDH 5’-CCAGCCGAGCCACATCGCTC-3’ Forward
5’-ATGAGCCCCAGCCTTCTC-3’ Reverse
IFN-γ ELISPOT
HLA-A*02+ AML patients were identified by flow cytometry
staining (BD Pharmingen, San Jose, CA) of the whole blood.
To identify AML patients which contained CTAG responsive
T cells IFN-γ release was measured by ELISPOT (eBioscience,
San Diego, CA). In brief, 96-well PDVF plates were coated
with IFN-γ capture antibody. PBMCs were thawed and plated
in the presence of CTAG peptides (20 ng/ml). Influenza GIL
and EBV YVL peptides were used as positive controls. After
36 hr, the plates were washed and biotinylated detection anti-
body added. Avidin-HRP solution was added and the plate
incubated for 45 min after a further wash, substrate solution
was added, and left to develop until spots developed, at which
point the reaction was terminated by washing, and the plate
was left to dry. Spots were counted using a ELISPOT reader.
Peptides List
LAGE SLLMWITQC
RAGE LKLSGVVRL
TRAG3 ILLRDAGLV
SSX2 KASEKIFYV
NYESO SLLMWITQC
SART3 LLQAEAPRL
MAGEA10 GLYDGMEHL
MAGEA4 GVYDGREHTV
MAGEA8 KVAELVHFL
MAGEA12 FLWGPRALV
MAGEA1 KVLEYVIKV
What’s new?
To date, cellular immunotherapy strategies against acute myeloid leukaemia (AML) have demonstrated limited efficacy. Here,
arginine concentrations in AML patients were shown to be significantly lower than in healthy controls, both at diagnosis and
during immunomodulatory treatment. Although T cells were able to recognise and be activated by antigens expressed on AML
blasts, the low arginine microenvironment acted as a metabolic brake on T cell function and expansion. Targeting arginine
metabolism in AML patients should be an adjunct to current treatment strategies in order to enhance host anti-leukaemia
immunity and boost the activity of CAR-T or adoptive T cell therapies.
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MAGEA2 KMVELVHFL
MAGEB1/B2 FLWGPRAYA
MAGEC2 ALKDVEERV
Statistics
t-Tests (parametric) were used to determine the statistical
significance of the difference in paired observations between
two groups (GraphPad Prism, San Diego, CA). p values are
two-tailed and where values were <0.05,they were considered
statistically significant. A Kaplan–Meier survival curve was
generated using GraphPad PRISM.
Methodological information regarding cell lines, flow
cytometric analysis, mixed lymphocyte reactions, our AML
murine models, ELISA and engineered T cells can be found in
the supplements.
Results
T cells are functionally exhausted despite enhanced cancer-
testis antigen expression on AML blasts
Epigenetic modifying drugs such as azacitidine and vorinostat
may boost the anti-leukaemia T cell immune response by
upregualting Cancer-Testis Antigens expression.6,7 First we
showed that treatment of AML cell lines with Azacitidine and
Vorinostat can upregulate MAGE, LAGE, RAGE, TRAG3,
and SSX2 CTAGs on AML tumour cell lines (Supporting
Information Fig. S1a). Recently we investigated the clinical
efficacy of combining azacitidine with vorinostat in a Phase II
trial in AML and high risk MDS patients.5 Although a num-
ber of clinical responses were seen, vorinostat provided no
additional clinical benefit in terms of overall survival. We
hypothesised that these drugs should have upregulated CTAGs
in AML blasts making them a more attractive immune target.
However, the mechanism of why the T cell response is inade-
quate to control the disease is unknown.
CTAGs are expressed in the context of HLA-A*02. Analy-
sis of AML blasts from HLA-A*02 patients on the AZA/VOR
clinical trial after three and six cycles of therapy identifies
upregulation of the five families of CTA expression (MAGE,
RAGE, LAGE, SSX2 and TRAG3) compared to before drug
administration in individual patients (Fig. 1a) confirming our
hypothesis. On recognition of target antigens, classically T
cells respond through cell division, IFN-γ release and cytotox-
icity. Patient-derived PBMC from 30 HLA-A*02 patients were
isolated before and during treatment (Supporting Information
Fig. S1b), and pulsed with relevant CTAG peptides ex vivo.
Increased activated anti-CTAG T cells for MAGE, LAGE, and
SSX2 antigens were particularly prominent as assessed by
release of IFN-γ release after AZA/VOR (Fig. 1b, Supporting
Information Fig. S1c and d). However, although the drugs led to
significant increase in antigen-specific T cell activation compared
to baseline, surprisingly, these responses are not greater than
those of healthy donors (Supporting Information Fig. S2a).8
We hypothesised that T cells in patients may be function-
ally exhausted—a state characterised by a failure to expand in
response to stimulation and upregulation of cell surface inhib-
itory receptors such as PD1, LAG3 and TIM3.16 First, we
identified that in the majority of patients T cells had a signifi-
cantly reduced ability to proliferate (p = 0.0078) compared to
those from healthy donors (Fig. 1c). Phenotyping demon-
strated upregulated PD1 expression (p = 0.0001) throughout
treatment, with no changes in LAG3 or TIM3 (Fig. 1d,
Supporting Information Fig. S2b and c). Thus, the expected
physiological expansion of activated T cells in response to
antigens on AML blasts is absent.
The failure to address the low arginine microenvironment
impairs anti-CTAG clinical responses
Arginine metabolism is a pathway which is aberrant in AML
blasts and can influence the immune microenvironment.4,9
Using an immunocompetent, syngeneic model of AML, we
showed that significant numbers of AML blasts (CD45.2+)
were detectable in the bone marrow (median 80%) and spleens
(median 40%) of mice, analogous to presentation of AML in
patients (Supporting Information Fig. S2d and e). AML bearing
mice showed significant reductions in the percentage of T cells
in the bone marrow (p = 0.0002) and spleens (p = 0.0002;
Fig. 1e) which also expressed increased PD1 (bone marrow
p = 0.0002, spleens p = 0.0011) consistent with our human
findings (Fig. 1f ). The mice had significant reductions in
plasma arginine compared to controls (p = 0.0031; Fig. 1g).
Nonself-antigen presentation by an allogeneic MHC is a
profound model of T cell stimulation and proliferation. To
investigate the specific impact of plasma arginine concentra-
tions, we first identified in vitro that T cell expansion in
response to allogeneic dendritic cells was profoundly inhibited
by the addition of recombinant human arginase to mimic
AML blast activity (Fig. 2a) with a corresponding reduction in
activation-induced IFN-γ release (Fig. 2b). Next equal num-
bers of human T cells (10 × 106) were engrafted into NOG-
SCID mice. T cells rapidly engrafted in the spleen (n = 14 days).
Analogous to the arginine deplete microenvironment found in
patients at diagnosis, administration of recombinant arginase
led to a significant reduction in serum arginine (p = 0.001;
Fig. 2c) and a failure of T cells to expand (p = 0.011; Fig. 2d).
Notably overall survival was prolonged by the effects of argi-
nine deprivation on T cells in these mice which otherwise
develop Graft Versus Host Disease lethality from T cell
responses to allo-antigens (p = 0.049; Fig. 2e).
Next we investigated the contribution of arginine metabo-
lism on T cell responses in the trial patients. Arginase II can
be regulated by histone deacetylases in nonmalignant cells,
therefore we hypothesised that the AZA/VOR may also down-
regulate arginase activity in AML blasts.10 Culture of AML cell
lines with azacitidine and vorinostat did not decrease arginase
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Figure 1. Azacitidine and Vorinostat induce an upregulation of Cancer-Testis Antigens in AML blasts. (a) AML patients treated with azacitidine
and vorinostat have increased expression of MAGE, LAGE, RAGE, TRAG3 and SSX2 Cancer-Testis Antigens in AML blasts at Cycle 3 and Cycle
6 compared to at the time of study enrolment. Expression assessed by qRT-PCR in n = 40 patients. Baseline expression is shown by the red
line (fold change 1). (b) Antigen-specific T cells from patients treated with azacitidine and vorinostat demonstrated increased IFN-γ release in
response to CTAG peptide stimulation ex vivo. IFN-γ positive T cells were measured by ELISPOT. (c) T cells from AML patients have a reduced
proliferative capacity compared to those from healthy donors, in response to CD3/CD28 antibody stimulation. (d) Expression of exhaustion
marker PD1 was assessed on CD3+ T cells from the blood of AML patients during treatment. (e) MLL-AF9 AML engrafted mice have
significantly reduced T cell numbers in the bone marrow and spleen compared to healthy controls as assessed by flow cytometry. (f ) T cells
from the bone marrow and spleens of engrafted mice have increased PD1 expression compared to healthy controls, as assessed by flow
cytometry. (g) AML mice have a significant reduction in plasma arginine concentrations compared to healthy controls.
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Figure 2. Arginase activity inhibits allogenic T cell responses. (a) Recombinant arginase leads to inhibition of T cell proliferation in allogeneic
mixed leukocyte reactions. Five representative donors shown. (b) Culture of T cells from healthy donors in complete media (R10%) or arginine
depleted media leads to a significant reduction in IFN-γ release in response to CD3/CD28 antibody stimulation. (c) Administration of
recombinant arginase to NOG-SCID mice engrafted with human lymphocytes leads to a significant reduction in plasma arginine. (d)
Recombinant arginase leads to a significant reduction in the frequency of T cells in the spleens of NOG-SCID mice engrafted with human
lymphocytes, as assessed by flow cytometry. (e) Kaplan–Meier survival curves showing NOG-SCID mice engrafted with human T cells have
increased survival after treatment with recombinant arginase. (f ) Arginase activity of AML cell lines after treatment with azacitidine and/or
vorinostat. (g) Concentration of arginine in the supernatants of AML cell lines after treatment with azacitidine and/or vorinostat.
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enzyme activity (Fig. 2f ) or supernatant arginine concentra-
tions (Fig. 2g). Consistent with this, analysis of patients’ AML
blasts demonstrated no change in Arginase II over time (Fig. 3a).
Patients maintained an increase in plasma Arginine II enzyme
(Fig. 3b, p = 0.0002) and significant reduction in arginine con-
centrations (Fig. 3c, p = 0.0001) throughout the trial. Therefore,
the arginine deplete environment remains throughout therapy
and can inhibit antigen-dependent T cell responses in vitro and
in vivo.
Targeting arginine metabolism enhances T cell
immunotherapy responses
Arginine catabolism appears to be a critical factor in holding
back the immune response to antigen on AML blasts. We
therefore investigated if targeting Arginase II enzyme activity
could enhance the T cell response in vitro. L-NMMA and
NOHA are two arginine analogues which can lead to revers-
ible inhibition of arginine metabolism in vitro. Human T cells
and purified AML blasts were first co-cultured, in the presence
of stimulatory allogeneic dendritic cells. AML blasts inhibited
T cell proliferation replicating our murine findings. However,
inhibition of arginase activity with L-NMMA and L-NOHA
led to restoration of T cell proliferation. (Supporting Informa-
tion Fig. S3a).
NY-ESO-1 is an established AML-associated cancer-testis
antigen that can be presented by HLA-A2 positive blasts
(Supporting Information Fig. S3b).6 Patient antigen-specific
CTAG responses can be modelled through the selection and
expansion of anti-NY-ESO T cells ex vivo, a process latterly
used to generate adoptive immunotherapy. In co-cultures
engineered anti-NY-ESO T cells alone had no effect on K562
AML viability, including after K562 cells were pretreated with
azacitidine and vorinostat (Fig. 3d). Although no additional
upregulation of NY-ESO was detected on K562 (Supporting
Information Fig. S3C), the arginase inhibitors enhanced engi-
neered anti-NY-ESO T cell cytotoxicity, leading to a further
significant reduction in the number of viable K562 cells
(p = 0.001; Fig. 3d).
We hypothesised that arginine metabolism may be simi-
larly contributing to the failure of other antigen-specific T cell
immune therapies. Clinical responses with CAR-T cell therapy
for AML have lagged behind the notable successes in Acute
Lymphoblastic Leukaemia, despite the presence of viable anti-
genic targets.11,12 The mechanism of failure is poorly under-
stood. CAR-T cell proliferation was assayed in normal and
low arginine conditions. Low arginine conditions significantly
inhibited CAR-T cell proliferation (Fig. 3e). Incubation of
anti-CD33 CAR-T cells with K562 led to a reduction in the
number of viable AML cells (p = 0.022; Fig. 3f ). Inhibition of
arginine metabolism enhanced CAR-T cell cytotoxicity against
the AML cells and led to a further significant reduction in via-
ble AML cells (p = 0.003; Fig. 3f ) Azacitidine and vorinostat
did not affect CAR-T cell cytotoxicity. Therefore, like autolo-
gous immune responses, engineered T cells have the capacity
to recognise and kill AML blasts but their full potential is not
realised until arginine metabolism is targeted and inhibited.
Discussion
The aberrant expression of Cancer-Testis Antigens offers the
potential to use a patient’s immune system, or engineered
immune therapies, to target AML. A number of CTAs includ-
ing SCP1, MAGE, SPAN-Xb, SLLP1 and PRAME CTAs have
been identified in unmanipulated AML blasts and may corre-
late with an improved overall survival.13–15 In the RAAVA
Phase II trial patients, we showed that azacitidine and vorino-
stat increased expression of a number of CTAGs not previously
reported such as LAGE, TRAG3 and SART3. Circulating T
cells demonstrated the capacity to be activated in response to
target antigen, thus epigenetic modifiers can act as immune
modulators. However, as in previous clinical studies, two obser-
vations are pertinent which have not been adequately justified
to date. The first is that the number of CTAG responding T
cells is small despite the large blast and antigenic burden. In
the case of MAGE, these antigen-specific T cells may constitute
less than 1% of the total CD8+ T cell pool, an insignificant
number considering the rapid rate of leukaemia cell division.
The second observation is that despite the presence of antigen
and circulating responsive T cells there is no correlation with
overall response to epigenetic modifying drugs. For adoptive T
cell combinations, epigenetic modulation has mostly been
tested in solid tumours, with only one phase I trial reporting
encouraging results using decitabine to boost a NY-ESO-1
vaccine for human ovarian cancer.16–18
Our findings are the first to report the clinical impact of
the low arginine microenvironment on immune therapy
approaches in patients, and extend our preclinical findings on
the role of tumour arginine metabolism in suppressing immu-
nity.4,19 In the case of AML blasts, arginine catabolism is a
function of their Arginase II enzyme,9 in combination with a
failure to express a full complement of arginine recycling
enzymes, making blasts reliant on extracellular sources of argi-
nine.20 The increased metabolic requirement for arginine by
activated T cells is clear, with arginine also contributing to T
cell survival through BAZ1B, PSIP1 and TSN signalling.21 In
our study, no correlation of T cell responses and patient clinical
outcome was seen, suggesting that any immune responses are
inadequate in the low arginine microenvironment. Attempts to
reactivate autologous immunity or enhance cellular immuno-
therapy therefore require not only availability of antigen expres-
sion but must also address the immunosuppressive metabolic
microenvironment which acts as constraint to cellular expan-
sion. Although epigenetic modifying drugs may influence mul-
tiple pathways, the study demonstrated they cannot help to
downregulate Arginase II expression.
Our study has important translational implications and
help to explain the functional impairment in T cells seen in
trials of peptide vaccines in AML patients or more recently
with CAR-T cells.22 A more direct approach to metabolic
2206 Targeting arginine metabolism to enhance immunotherapy
Int. J. Cancer: 145, 2201–2208 (2019) © 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
T
um
or
Im
m
un
ol
og
y
an
d
M
ic
ro
en
vi
ro
n
m
en
t
Baseline Cycle 3 Cycle 6 
0
1
2
3
4
A
R
G
II 
(F
ol
d 
ch
an
ge
)
ns ns
ns
Healthy
0
50
100
150
200
ÿ
ÿ
%
$
A
rg
in
in
e 
(m
M
)
p=0.0001
Baseline Cycle 3 Cycle 6
Patients
p=0.02
ns
Baseline Cycle 3 Cycle 6 Healthy
0
50
100
150
200
200
250
300
350
400
ÿ
ÿ
%
$
A
rg
in
as
e 
II 
(n
g/
m
l)
p=0.0002
ns
ns
-inhibitors +inhibitors
0
1000
2000
3000
4000
5000
N
um
be
r o
f v
ia
bl
e 
ce
lls
 
K562 co-cultured with 
CD33 CAR T cells
K562 alone 
p=0.022 p=0.003
Untreated +AZA/VOR treated
N
um
be
r 
of
 v
ia
bl
e 
C
A
R
 T
 c
el
ls
-inhibitors
+NY-ESO T cellsalone 
0
5000
10000
15000
20000
25000
N
um
be
r o
f v
ia
bl
e 
K
56
2 
ce
lls
 
K562 untreated
+AZA/VOR
p<0.0001
p<0.0001
+NY-ESO T cellsalone 
+inhibitors
R10% Arginine Depleted R10%
0
10000
20000
30000
40000 p=0.02
Patients
(a) (b)
(c) (d)
(e) (f)
Figure 3. Inhibition of arginine metabolism enhances T cell immunotherapy cytotoxicity against AML. (a) AML patients treated with azacitidine
and vorinostat have no significant changes in Arginase II expression in AML blasts at Cycle 3 and Cycle 6 compared to at the time of study
enrolment. Expression assessed by qRT-PCR. (b) Plasma Arginase II concentrations are elevated in AML patients, compared to healthy controls,
and are not significantly altered after cycles of azacitidine and vorinostat treatment. (c) Plasma arginine concentrations are decreased in AML
patients, compared to healthy controls, and are not significantly altered after cycles of azacitidine and vorinostat treatment. (d) Anti-NY-ESO
antigen-specific T cells were cultured with K562 (target) AML cells. The numbers of viable K562 cells was significantly reduced if antigen-specific
T cells are used in combination with inhibitors of AML arginine metabolism (+inhibitors: L-NMMA and NOHA). Pretreatment with azacitidine and
vorinostat did not affect cytotoxicity. (e) Anti-CD33 CAR-T cell proliferation is inhibited when cultured in arginine depleted media. CAR-T cell
numbers were counted by flow cytometry after 72 hr. (f ) Anti-CD33 CAR-T cells were cultured with K562 (target) AML cells. The numbers of viable
K562 cells were reduced by CAR-T cells alone. The numbers of viable K562 cells was further reduced if AML arginine metabolism is inhibited
(+inhibitors: L-NMMA and NOHA). Pretreatment with azacitidine and vorinostat did not affect cytotoxicity.
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modulating therapy would be to target the Arginase II
enzyme’s active site. A multitude of novel inhibitors have
sought to target arginase enzymes, mostly with limitations
such as reversibility, a failure to cross the cell membrane, or
the need to block both Arginase and INOS enzymes if present
in cancer cells.23,24 The most clinically advanced arginase
inhibitor is CB-1158 (Calithera), an orally active agent that is
undergoing clinical trial alongside checkpoint inhibitors in
patients with advanced solid tumours (NCT02903914).
Alternatives could include screening of patients’ plasma for
arginine concentrations to ensure T cell therapies are adminis-
tered at an optimal time point, or administration of T cell
therapies with an arginine supplemented diet. The later
approach has been used with mixed results to enhance healing
postsurgery, but may have untoward effects of feeding tumour
metabolism. As a number of cancers which are targets for T
cell immunotherapies deplete arginine through aberrant
arginine recycling pathways, future strategies should seek to
urgently address this significant metabolic challenge.25
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